Oxford Biomedica EQT talks highlight the biotech investor’s interest, despite previous rejections of bids deemed undervalued.
Browsing: M&A and Licensing
News and insights on mergers, acquisitions, licensing deals, and strategic collaborations across the global pharma industry.
AbbVie invests $650 million in a dual-targeting immunotherapy from RemeGen, enhancing its oncology portfolio.
Lilly Ventyx acquisition for $1.2B focuses on NLRP3 inflammasome drugs, expanding Lilly’s immune drug pipeline.
Amgen acquires Dark Blue for up to $840M, gaining a protein-degrading drug targeting acute myeloid leukemia.
BioMarin Amicus acquisition for $4.8B adds a late-stage asset and two marketed therapies generating $450M in nine months.
BioMarin Amicus acquisition valued at $4.8 billion adds a late-stage asset and two marketed therapies generating $450 million.
Xoma acquires Generation Bio, a gene therapy developer, in a strategic move to enhance its biotech portfolio.
Pfizer obesity pill China deal involves a $2 billion agreement with Fosun Pharma, aiming to enhance its weight loss medication offerings.
Mirum Bluejay acquisition secures a late-stage hepatitis D drug, enhancing its pipeline with potential $200M in additional payouts.
Contingent value rights are increasingly used in biotech deals, bridging price gaps amid market turbulence.